Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan for Early-Stage Low-Risk PAH
NCT06987097Not yet recruiting
- Sponsor
- Nanjing First Hospital
- Start
- May 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Ambrisentan with Placebo (2 arms). Primary endpoint: Composite of pulmonary hypertension progression at 12 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06987097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06987097.